Public release date: 31-May-2012 [ | E-mail | Share ] <\/p>\n
Contact: Erin Tornatore erin.tornatore@childrens.harvard.edu<\/a> 617-919-3110 Children's Hospital Boston<\/p>\n Boston, Mass. Using advanced technologies for rapidly sequencing and analyzing DNA from clinical and pathologic samples, a multidisciplinary research team consisting of geneticists, pathologists and surgeons at Boston Children's Hospital has identified the genetic basis for CLOVES syndrome, a rare congenital malformation and overgrowth disorder. <\/p>\n The discovery raises the hope that, for the first time, it will be possible to develop targeted medical treatments capable of delaying, reversing or possibly preventing CLOVES's debilitating consequences. Importantly, it also demonstrates the potential of advanced DNA sequencing technologies for identifying the underlying molecular roots of malformation disorders that are genetic but not hereditary. <\/p>\n The teamled by Matthew Warman, MD, director of the Orthopedic Research Laboratories at Boston Children's, and Kyle Kurek, MD, of the hospital's department of Pathology, and members of the hospital's Vascular Anomalies Centerreported the discovery today in the online edition of the American Journal of Human Genetics. <\/p>\n Some 90 children worldwide have been diagnosed with CLOVES (which stands for Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevis, Spinal\/skeletal anomalies\/scoliosis) since 2006, when the condition was first characterized by Boston Children's Ahmad Alomari, MD, and investigators at the National Institutes of Health. Alomari co-directs the Vascular Anomalies Center with Steven Fishman, MD, and John Mulliken, MD; all three are authors on the paper. <\/p>\n The clinical features of CLOVESin general a combination of fatty growths in the torso, vascular and skin anomalies, overgrowth in or deformities of limbs or extremities and spinal problems such as scoliosiscan vary greatly from child to child. Presently there is no cure for CLOVES, only surgical treatments aimed at alleviating symptoms or managing the syndrome's progression. <\/p>\n Until now, the exact nature of the genetic defect or defects that cause CLOVES has remained a mystery. <\/p>\n \"CLOVES is dynamic, presenting itself in new ways all the time, even within the same patient,\" said Fishman, who with Alomari and others in the Vascular Anomalies Center has treated numerous children with CLOVES. \"With this discovery we are optimistic that it will now be possible to develop treatments that take less of a shotgun approach and which could prevent the syndrome's progression.\" <\/p>\n The researchers started from the assumption that CLOVES is genetic but not inherited, because the syndrome always appears sporadically and is never passed from affected parents to their children; nor do the parents of affected children show signs of the syndrome. <\/p>\n<\/p>\n See the original post here:<\/p>\n Researchers at Boston Children's Hospital identify a genetic cause for CLOVES syndrome<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Public release date: 31-May-2012 [ | E-mail | Share ] Contact: Erin Tornatore erin.tornatore@childrens.harvard.edu<\/a> 617-919-3110 Children's Hospital Boston Boston, Mass. Using advanced technologies for rapidly sequencing and analyzing DNA from clinical and pathologic samples, a multidisciplinary research team consisting of geneticists, pathologists and surgeons at Boston Children's Hospital has identified the genetic basis for CLOVES syndrome, a rare congenital malformation and overgrowth disorder. The discovery raises the hope that, for the first time, it will be possible to develop targeted medical treatments capable of delaying, reversing or possibly preventing CLOVES's debilitating consequences. Continue reading